Biomaterials – vaccines articles from across Nature Portfolio

Featured

News & Views | 02 March 2023

Immunostimulatory nanoparticles go viral
- Jorge Huete-Carrasco
- & Ed C. Lavelle
Nature Materials 22, 273-275

Latest Research and Reviews

Research
11 February 2023 | Open Access

A cooperative nano-CRISPR scaffold potentiates immunotherapy via activation of tumour-intrinsic pyroptosis

Delivery of immune therapy drugs to tumours might be hampered by their limited bioavailability and the difficulty of targeting complex exogenous compounds. Here authors trigger immunologic cell death, via activating tumour-cell-intrinsic pathways via CRISPR-based nanotechnology to enable efficient anti-tumour immune response in mouse models of melanoma.
- Ning Wang
- , Chao Liu
- & Changyang Gong
Nature Communications 14, 779
Research
02 December 2022 | Open Access

Immunosuppressive biomaterial-based therapeutic vaccine to treat multiple sclerosis via re-establishing immune tolerance

Multiple sclerosis is a debilitating autoimmune disease, for which therapy is not curative, only slowing down progression at the expense of general immune suppression. Here authors show that in a mouse model of multiple sclerosis, disease progression could be halted or even reversed by a nanovaccine, composed of reactive oxygen species scavenging cerium oxide nanoparticles, which establishes immune tolerance against the relevant autoantigen.
- Thanh Loc Nguyen
- , Youngjin Choi
- & Jaeyun Kim
Nature Communications 13, 7449
Research
01 November 2022 | Open Access

In situ generation of micrometer-sized tumor cell-derived vesicles as autologous cancer vaccines for boosting systemic immune responses

Autologous tumor cell vaccines can elicit anti-tumor immune responses. Here, the authors report the design of dendritic polymer-based nanoparticles loaded with doxorubicin and the tyrosine kinase inhibitor apatinib that can induce immunogenic cell death and the in situ production of immuno-stimulatory micrometer-sized vesicles, promoting anti-tumor immune responses in preclinical models.
- Yuxin Guo
- , Shao-Zhe Wang
- & Fu-Gen Wu
Nature Communications 13, 6534
Research | 04 July 2022

Generation of a live attenuated influenza A vaccine by proteolysis targeting

Influenza virus is attenuated for vaccine production using PROTAC degradation technology.
- Longlong Si
- , Quan Shen
- & Roberto Plebani
Nature Biotechnology 40, 1370-1377
Research
22 October 2021 | Open Access

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation
- Pawan Dulal
- , Robabeh Gharaei
- & Alexander D. Douglas
Scientific Reports 11, 20877
Reviews | 28 September 2021

Designing spatial and temporal control of vaccine responses

The immune response to a vaccine is characterized by a complex time-dependent interplay between various cell types and molecules in different tissues in our body. This Review explores materials-based strategies for the spatial and temporal control of the mechanisms that underlie vaccine immune responses.
- Gillie A. Roth
- , Vittoria C. T. M. Picece
- & Eric A. Appel
Nature Reviews Materials 7, 174-195

All Research & Reviews

News and Comment

News & Views | 02 March 2023

Immunostimulatory nanoparticles go viral

A polymeric nanoparticle adjuvant containing a Toll-like receptor 7 agonist elicits broad protection against viral challenges.
- Jorge Huete-Carrasco
- & Ed C. Lavelle
Nature Materials 22, 273-275
Comments & Opinion | 24 January 2023

Biomaterials for intranasal and inhaled vaccine delivery

Delivery of vaccines by nasal sprays may enable more robust, protective mucosal immune responses against infectious diseases, such as COVID-19, compared with intramuscular injection. In this Comment, we highlight how biomaterials can be designed to allow intranasal and inhaled vaccination.
- Devorah Cahn
- , Mayowa Amosu
- & Gregg A. Duncan
Nature Reviews Bioengineering 1, 83-84
News & Views | 20 December 2022

Towards a universal flu vaccine
- Cristina Lo Giudice
Nature Materials, 1
News & Views | 22 January 2019

Next-generation malarial vaccines

A vaccine platform developed from a synthetic polymeric glyco-adjuvant and reversibly conjugated to an antigen was shown to target dendritic cells leading to cellular and humoral immune response against malaria.
- Yvette van Kooyk
Nature Materials 18, 94-96
News & Views | 09 August 2018

Combined local and systemic attacks

Intratumoral injection of a hydrogel impregnated with radioisotope-labelled catalase and an immunostimulant, along with systemic immune checkpoint blockade, inhibits tumour growth in mouse models of localized cancer and metastatic cancer.
- Catherine S. Spina
- & Charles G. Drake
Nature Biomedical Engineering 2, 564-565
Editorial | 23 May 2018

Cells and materials in immunotherapy

As the interaction of the immune system with the tumour microenvironment becomes increasingly understood, more evidence indicates how immunotherapy can be employed to better eliminate cancers.

Nature Materials 17, 471